Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Outstanding
Ratios

Tango Therapeutics (TNGX) Accumulated Depreciation & Amortization (2020 - 2025)

Historic Accumulated Depreciation & Amortization for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $10.1 million.

  • Tango Therapeutics' Accumulated Depreciation & Amortization rose 2992.38% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year increase of 2992.38%. This contributed to the annual value of $8.4 million for FY2024, which is 3963.93% up from last year.
  • Latest data reveals that Tango Therapeutics reported Accumulated Depreciation & Amortization of $10.1 million as of Q3 2025, which was up 2992.38% from $9.6 million recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' Accumulated Depreciation & Amortization ranged from a high of $10.1 million in Q3 2025 and a low of $2.3 million during Q3 2021
  • Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $5.4 million (2023), whereas its average is $5.7 million.
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first surged by 6815.9% in 2023, then soared by 2992.38% in 2025.
  • Tango Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $2.5 million in 2021, then skyrocketed by 45.55% to $3.7 million in 2022, then skyrocketed by 62.7% to $6.0 million in 2023, then skyrocketed by 39.64% to $8.4 million in 2024, then grew by 20.29% to $10.1 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $10.1 million for Q3 2025, versus $9.6 million for Q2 2025 and $9.0 million for Q1 2025.